J. Pers. Med. 2012, 2(4), 257-266; doi:10.3390/jpm2040257

Aligning the Economic Value of Companion Diagnostics and Stratified Medicines

Integrated Medicines Ltd., Topfield House, Ermine Street, Caxton, Cambridge, CB23 3PQ, UK
* Author to whom correspondence should be addressed.
Received: 1 October 2012; in revised form: 9 November 2012 / Accepted: 12 November 2012 / Published: 26 November 2012
PDF Full-text Download PDF Full-Text [668 KB, uploaded 26 November 2012 08:54 CET]
Abstract: The twin forces of payors seeking fair pricing and the rising costs of developing new medicines has driven a closer relationship between pharmaceutical companies and diagnostics companies, because stratified medicines, guided by companion diagnostics, offer better commercial, as well as clinical, outcomes. Stratified medicines have created clinical success and provided rapid product approvals, particularly in oncology, and indeed have changed the dynamic between drug and diagnostic developers. The commercial payback for such partnerships offered by stratified medicines has been less well articulated, but this has shifted as the benefits in risk management, pricing and value creation for all stakeholders become clearer. In this larger healthcare setting, stratified medicine provides both physicians and patients with greater insight on the disease and provides rationale for providers to understand cost-effectiveness of treatment. This article considers how the economic value of stratified medicine relationships can be recognized and translated into better outcomes for all healthcare stakeholders.
Keywords: stratified medicines; economic value; health outcomes; multiple stakeholders; companion diagnostic; regulation; reimbursement

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Blair, E.D.; Stratton, E.K.; Kaufmann, M. Aligning the Economic Value of Companion Diagnostics and Stratified Medicines. J. Pers. Med. 2012, 2, 257-266.

AMA Style

Blair ED, Stratton EK, Kaufmann M. Aligning the Economic Value of Companion Diagnostics and Stratified Medicines. Journal of Personalized Medicine. 2012; 2(4):257-266.

Chicago/Turabian Style

Blair, Edward D.; Stratton, Elyse K.; Kaufmann, Martina. 2012. "Aligning the Economic Value of Companion Diagnostics and Stratified Medicines." J. Pers. Med. 2, no. 4: 257-266.

J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert